Prostate Cancer Treatment Effectiveness Could Rely on P53
A study led by the Fred Hutchinson Cancer Research Center suggests that tumors with intact P53 genes may respond better to prostate cancer treatments designed to target insulin-like growth factor 1 receptors (IGF-1R).
Fred Hutchinson’s findings could have an important impact on more than a dozen clinical trials currently being conducted to test IGF-1R inhibitors.
Previous research has shown elevated IGF-1R levels increase the risk of prostate cancer, but Fred Hutchinson’s comparison of transgenic mice with intact p53 genes and compromised p53 genes revealed that deleting IGF-1R promoted aggressive prostate cancers in the mice with compromised p53.
Since p53 status was not part of the criteria considered for participants in the inhibitor trials, clinicians administering treatments targeting IGF-IR will need to give this new data careful consideration. As one of the study’s authors said,
“If our predictions hold true, tumor cells with intact p53 may show the best response to therapy targeting the IGF-1R signal, however when p53 is not functioning normally, response to this therapy may not be as expected.”
“We’re all hoping for good results but let’s proceed with caution.”
Norman Greenberg, PhD
Clinical Research Division
Fred Hutchinson Cancer Research Center
If you’d like to learn more, the team’s findings have been published in the May 1, 2008, edition of Cancer Research.
Source: Fred Hutchinson Cancer Research Center News
Related Links: womenshealth.gov; American Cancer Society
Technorati Tags: oncology; urology; male cancers; genitourinary carcinoma; Seattle, WA
Print This
|
| Sphere: Related Content
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URI
Leave a comment
Browse All Categories: Next article: Lipidoids Could Deliver RNAi Treatments Directly to Cancer
Previous article: Mayo Clinic Oncologists Answer Cancer Questions Online
